Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +207.46%
#3 ONFA ONFA +54.25%
#4 Metaplex Metaplex +23.40%
#5 Osaka Protocol Osaka Protocol +21.54%
#6 Wrapped Krown Wrapped Krown +20.00%
#7 Talus Network Talus Network +19.98%
#8 DODO DODO +17.78%
#9 Black Phoenix Black Phoenix +15.09%
#10 Magma Finance Magma Finance +14.74%
Coin of the day
DeFiChain DeFiChain
Settings
Language
ENGLISH
Currency
USD
Theme
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Rank in Stocks #16324
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Share Price
$0.94180721
Market Cap
$22.26M
Change (1 day)
0.38%
Change (1 year)
-14.35%
Country
FR
Trade Valbiotis SA (ALVAL)

Category

Healthcare
Number of shares outstanding for Valbiotis SA (ALVAL)
Number of shares outstanding as of December 2025: 23.69M
According to Valbiotis SA latest financial reports and stock price the company's current number of shares outstanding is 23.69M. At the end of December 2023 the company had 12.46M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Valbiotis SA (ALVAL) from 2015 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 23.69M 50.02%
2024 15.79M 26.74%
2023 12.46M 23.21%
2022 10.11M 10.45%
2021 9.16M 22.88%
2020 7.45M 58.63%
2019 4.70M 24.66%
2018 3.77M 42.50%
2017 2.64M -26.12%
2016 3.58M 29,318.19%
2015 12.17K 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.44B 18,649.65%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 254.10M 972.42%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 104.00M 338.93%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M 701.88%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 61.42M 159.22%
NL